Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 3:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 184 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Depression, Burnout, Professional
Interventions
Psilocybin, Mindfulness-Based Stress Reduction (MBSR)
Drug · Behavioral
Lead sponsor
University of Utah
Other
Eligibility
25 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Anhedonia, Emotional Blunting
Interventions
Psilocybin, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
New York, New York
Conditions
Amphetamine-Related Disorders
Interventions
Psilocybin, Treatment-as-usual
Drug · Behavioral
Lead sponsor
Portland VA Research Foundation, Inc
Other
Eligibility
25 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Vancouver, Washington
Conditions
PTSD, Stress Disorders, Traumatic, Stress Disorders, Post-Traumatic, Trauma and Stressor Related Disorders, Mental Disorder
Interventions
Psilocybin
Drug
Lead sponsor
Ohio State University
Other
Eligibility
21 Years to 64 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Not yet recruiting Phase 1 Interventional

Psilocybin After Trauma Surgery for Pain

NCT07406828
Conditions
Pain Management, Postoperative Pain
Interventions
Psilocybin (Usona Institute), Postoperative analgesia
Drug
Lead sponsor
Trent Emerick
Other
Eligibility
25 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Not yet recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

The Acute Effects of Psilocybin on Cognition, Memory, and Brain Function

NCT07079852
Conditions
Healthy
Interventions
Placebo, Psilocybin 15mg
Drug
Lead sponsor
Manoj Doss
Other
Eligibility
21 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Austin, Texas
Conditions
Treatment Resistant Depression, Substance Use Disorders
Interventions
Psilocybin
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
2
States / cities
Indianapolis, Indiana
Conditions
Perception Disorders
Interventions
Psilocybin
Drug
Lead sponsor
University of California, Berkeley
Other
Eligibility
21 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Berkeley, California
Conditions
Hospice, Psilocybin, Demoralization, Terminal Illness, Cancer-related Problem/Condition, Psychotherapy, Terminal Cancer, Cancer Terminal
Interventions
Psilocybin, Psychotherapy
Drug · Behavioral
Lead sponsor
Yvan Beaussant, MD, MSci
Other
Eligibility
21 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Danvers, Massachusetts
Conditions
Depression
Interventions
Psilocybin (Usona Institute)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Major Depressive Diorder
Interventions
Psilocybin (drug), cognitive behavioral therapy, Minimal supportive therapy
Drug · Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Psilocybin, Hallucinogens, Pharmacologic Actions, Central Nervous System Agents, Therapeutic Uses, Psychotropic Drugs
Interventions
psilocybin
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
25 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Opioid Use Disorder
Interventions
Psilocybin
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 65 Years
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
5
States / cities
Albuquerque, New Mexico • Brooklyn, New York • New York, New York + 1 more
Conditions
Major Depressive Disorder
Interventions
Low Dose Psilocybin, Placebo, Medium Dose Psilocybin
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
West Haven, Connecticut
Recruiting Phase 1 Interventional Accepts healthy volunteers

Open-Label Psilocybin Study in Transdiagnostic Population

NCT06442423
Conditions
Transdiagnostic, Depression - Major Depressive Disorder, Anxiety, PTSD Symptoms, PTSD, Substance Use, Substance Use Disorder (SUD), OCD
Interventions
Psilocybin
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Active, not recruiting Early Phase 1 Interventional

Effects of Psilocybin in Obsessive Compulsive Disorder

NCT05546658
Conditions
Obsessive-Compulsive Disorder
Interventions
Psilocybin
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 80 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Not yet recruiting Phase 2 Interventional

Group PACBT for Depression

NCT07566104
Conditions
Depression - Major Depressive Disorder, Psilocybin, Cognitive Behavioral Therapy
Interventions
Psilocybin (drug), Group Cognitive Behavioral Therapy
Drug · Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Major Depressive Disorder, Anhedonia, Treatment Resistant Depression
Interventions
Psilocybin 25mg, Placebo (active placebo)
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
21 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Effects of Psilocybin on Electrophysiology and the Dynamic Content of Thought

NCT05301608
Conditions
Healthy
Interventions
Psilocybin, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Alcohol Use Disorder
Interventions
Psilocybin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
IBS - Irritable Bowel Syndrome
Interventions
Psilocybin 25 mg, Psychotherapy Treatment Session, Niacin 100 mg
Drug · Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
New York, New York
Conditions
Bipolar II Disorder, Depression, Bipolar, Suicidality
Interventions
Psilocybin, Therapeutic Support
Drug · Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
25 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Houston, Texas
Conditions
Alcohol Dependence
Interventions
Psilocybin
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
25 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Albuquerque, New Mexico
Not yet recruiting Phase 2 Interventional

Psilocybin-Assisted Therapy

NCT07332143
Conditions
PTSD
Interventions
psilocybin, Supportive Therapy, Prolonged Exposure Therapy
Drug · Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia